Physician profile
Daniel Orozco
NPI 1154329399
$2,168.05
in general payments reported to CMS, 2019-2025
29 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $159 · 2021: $740 · 2022: $236 · 2023: $237 · 2024: $28.74 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $336.59 | 2021-2025 | |
| Biogen, INC. | $260.81 | 2020-2025 | Vumerity, Tysabri |
| Ucb, INC. | $222.08 | 2019-2020 | |
| Sk Life Science, INC. | $153.61 | 2020-2021 | |
| Genzyme Corporation | $139.68 | 2021 | |
| Celgene Corporation | $117.03 | 2021-2025 | Zeposia |
| Glaxosmithkline, LLC. | $110.31 | 2021 | |
| Alexion Pharmaceuticals, INC. | $92.58 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $81.35 | 2019-2022 | |
| Mdd US Operations, LLC | $71.73 | 2020 | |
| Livanova USA, INC. | $69.58 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $65.84 | 2019-2025 | Austedo Xr |
| Allergan, INC. | $54.27 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $50.56 | 2019 | |
| Avion Pharmaceuticals | $45.94 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.55 | 2019 | |
| Sumitomo Pharma America, INC. | $29.97 | 2023 | Aptiom |
| Lilly USA, LLC | $24.59 | 2019 | |
| Amgen INC. | $24.01 | 2019 | |
| Vertical Pharmaceuticals, LLC | $23.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.95 | 2022 | |
| Argenx US, INC. | $20.54 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Pfizer INC. | $19.29 | 2025 | |
| Amneal Pharmaceuticals LLC | $17.77 | 2019 | |
| Eisai INC. | $16.90 | 2019 | |
| Neurocrine Biosciences, INC. | $15.98 | 2023 | Ingrezza, Ongentys |
| Emd Serono, INC. | $15.57 | 2019 | |
| Genentech USA, INC. | $13.69 | 2019 | |
| Lundbeck LLC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Orozco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.